Market Research Industry Reports

Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018

Summary

Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. The latest report Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

Furthermore, this report also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 7 (ITGA7) - Overview
Integrin Alpha 7 (ITGA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 7 (ITGA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development
Strykagen Corp
Integrin Alpha 7 (ITGA7) - Drug Profiles
Stryka-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-516s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-533 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-978 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
StrykaPro-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Strykagen Corp, H1 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2018

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2018Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein

USD 3500View Report

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1 2018

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H1

USD 3500View Report

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2018

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2018According to the recently published report Integrin Alpha V - Pipeline Review, H1 2018; Integrin

USD 3500View Report

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2018

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2018Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 15 molecules. Out of which approximately 13

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : Jun 2018
No. of Pages :26
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube